Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Gilead Sciences, Inc.

NASDAQ: GILD · Life Sciences · 12 alerts · CIK 882095

Share price
$167.58Close, Nov 16
Market cap
$208B
Shares outstanding
1.24BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gilead Sciences, Inc. filings on SEC EDGAR ↗

3:44 PM ET Form 4
Insider Selling

Gilead Sciences Insider Kelly A. Kramer Sells $1.76M of Stock

Kelly A. Kramer sold 10,376 shares of Gilead Sciences, Inc. at $168.23 to $171.44 a share (average $169.76) in 4 transactions, worth $1.76M in total on Nov 12, 2026. Shares held after the trade: 1,339 (-13.0%).

Value
$1.76M
Shares
10,376
Average price
$169.76
Holding change
-13.0%
Trade date
Nov 12, 2026
7:20 PM ET Form 4
Insider Selling

Gilead Sciences EVP Gen Counsel, Legal & Comp Wettan Keeley M. Cain Sells $558K of Stock

Wettan Keeley M. Cain, EVP Gen Counsel, Legal & Comp, sold 3,399 shares of Gilead Sciences, Inc. at $164.11 a share, worth $558K in total on Nov 6, 2026. Shares held after the trade: 5,360 (-38.8%).

Value
$558K
Shares
3,399
Price
$164.11
Role
EVP Gen Counsel, Legal & Comp
Holding change
-38.8%
Trade date
Nov 6, 2026
5:16 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $19.7M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 112,429 shares of Gilead Sciences, Inc. at $175.16 to $175.17 a share (average $175.16) in 2 transactions, worth $19.7M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 551,683 (-1.7%).

Value
$19.7M
Shares
112,429
Average price
$175.16
Role
Chairman & CEO
Holding change
-1.7%
Trade date
Nov 4, 2026 to Nov 5, 2026
7:15 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $5.33M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).

Value
$5.33M
Shares
30,881
Average price
$172.57
Role
Chairman & CEO
Holding change
-0.4%
Trade date
Oct 30, 2026 to Nov 2, 2026
6:09 AM ET 10-Q
Financial Results ▶ Call

Gilead Sciences Q3 2026 Results: Net Income $2.43B, Down 20.4% YoY

Gilead Sciences reported total revenues of $8.3 billion for the third quarter of 2026, driven by $8.29 billion in product sales. Despite a profitable third quarter, the company recorded a net loss of $6.05 billion for the first nine months of 2026, primarily due to $11.3 billion in acquired in-process research and development expenses.

Key figure
Net income $2.43B · -20.4% YoY
4:05 PM ET 8-K
Financial Results

Gilead Sciences Financial Results

Gilead Sciences reported third-quarter 2026 financial results, featuring a 13% increase in total product sales to $8.3 billion, driven by strong performance in its HIV portfolio. The company raised its full-year base business revenue guidance for the second time this year, citing robust demand for Biktarvy and HIV prevention products.

“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.”

Daniel O’Day, Gilead’s Chairman and Chief Executive Officer

“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.”

Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
4:17 PM ET Form 4
Insider Selling

Gilead Sciences CFO Andrew D. Dickinson Sells $469K of Stock

Andrew D. Dickinson, CFO, sold 3,000 shares of Gilead Sciences, Inc. at $156.22 a share, worth $469K in total on Oct 15, 2026. Shares held after the trade: 161,096 (-1.8%).

Value
$469K
Shares
3,000
Price
$156.22
Role
CFO
Holding change
-1.8%
Trade date
Oct 15, 2026
4:12 PM ET Form 4
Insider Selling

Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier Sells $469K of Stock

Johanna Mercier, Chief Comm & Corp Aff Officer, sold 3,000 shares of Gilead Sciences, Inc. at $156.22 a share, worth $469K in total on Oct 15, 2026. Shares held after the trade: 113,684 (-2.6%).

Value
$469K
Shares
3,000
Price
$156.22
Role
Chief Comm & Corp Aff Officer
Holding change
-2.6%
Trade date
Oct 15, 2026
4:40 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $2.22M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 15,000 shares of Gilead Sciences, Inc. at $147.72 to $148.63 a share (average $147.90) in 2 transactions, worth $2.22M in total on Oct 1, 2026. Shares held after the trade: 566,683 (-0.5%).

Value
$2.22M
Shares
15,000
Average price
$147.90
Role
Chairman & CEO
Holding change
-0.5%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.